NeoDynamics Announces Delivery of CorePulse Needles to 23 Hospitals

Rhea-AI Summary

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST) announced the shipment of its first production run of CorePulse needles to hospitals in the UK, Germany, and Switzerland, expected to arrive this month. This marks a significant step in the company's goal to enhance cancer diagnosis and care. The CorePulse needles will be delivered to 23 hospitals, including notable institutions such as The Royal Oldham Hospital and St Bartholomew's Hospital. Additionally, NeoDynamics is set to launch NeoNavia in the US, focusing on the FlexiPulse needle after successful trials in Europe.

Positive

• First production run of CorePulse needles shipped to 23 hospitals in UK, Germany, and Switzerland.
• Launch of NeoNavia in the US is on schedule, focusing on the FlexiPulse needle.

Negative

• None.

STOCKHOLM, April 3, 2023 /PRNewswire/ -- NeoDynamics AB (publ) (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced that the first production run of its CorePulse needles has been shipped and is anticipated to arrive with UK and German customers this month.

NeoDynamics is pleased it will now deliver CorePulse needles in April and VacuPulse needles by mid-year to the centres in Europe listed below.

The following hospitals will receive deliveries in April 2023:

UK	Germany and Switzerland
Nightingale Centre (Manchester)	Hermann-Joseph Krankenhaus (Erkelenz)
Leeds Teaching Hospital	Klinikzentrum Mitte (Dortmund)
Western General Hospital (Edinburgh)	Johanniter Bonn
Darlington Memorial Hospital	Marienhospital Bottrop
North Manchester General Hospital	Krankenhaus Düren
The Royal Oldham Hospital	Klinikum Stadt Soest
Cheltenham General Hospital	Klinikum Lüneburg
Wycombe Hospital	Klinikum Sternberg
Basildon University Hospital	Rotkreuzklinikum München
St Bartholomew's Hospital (St Barts)	Stadtspital Zürich Triemli
Northwick Park Hospital	Universitätsklinikum Köln
	Goethe Universität Frankfurt am

As the company continues to build out its US commercial team, the launch of NeoNavia in the US remains on schedule and will initially focus on the novel open-tip FlexiPulse needle which has been extensively trialled and used in UK and German hospitals over the past two years.

For further information, please contact:

Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com

Aaron Wong, CFO NeoDynamics AB,  phone +46735 972 011 or e-mail aaron.wong@neodynamics.com

 

View original content:https://www.prnewswire.com/news-releases/neodynamics-announces-delivery-of-corepulse-needles-to-23-hospitals-301788048.html

SOURCE NeoDynamics

FAQ

What are the recent developments for NeoDynamics (NEOD)?

NeoDynamics announced the shipment of CorePulse needles to 23 hospitals in the UK, Germany, and Switzerland.

When will CorePulse needles be delivered?

CorePulse needles are expected to arrive at hospitals in April 2023.

What markets is NeoDynamics targeting with NeoNavia?

NeoDynamics plans to launch NeoNavia in the US, focusing initially on the FlexiPulse needle.

Which hospitals will receive NeoDynamics' CorePulse needles?

Notable hospitals include The Royal Oldham Hospital and St Bartholomew's Hospital.